MedTrace Logo

Cytidine-phosphate-guanosine (CpG) DNA in Hepatocellular Carcinoma Combination Therapy

NCT03235167 · Status: UNKNOWN · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2017-09-18

No results posted yet for this study

Summary

to observe the outcome of hepatocellular carcinoma patients under the combination treatment of transcatheter arterial chemoembolization (TACE) and CpG DNA

Conditions

Interventions

DRUG

CpG DNA

CpG DNA concentrate

PROCEDURE

transcatheter arterial chemoembolization

transcatheter arterial chemoembolization (TACE) therapy for liver cancer

DRUG

Placebo - Concentrate

CpG DNA vehicle

Sponsors & Collaborators

  • Dalian University

    lead OTHER

Principal Investigators

  • xiaolin Yuan · Affiliated Zhongshan Hospital of Dalian University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
FACTORIAL

Eligibility

Min Age
55 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-10-31
Primary Completion
2022-10-31
Completion
2022-10-31

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03235167 on ClinicalTrials.gov